Down-regulation of Egr-1 by siRNA inhibits growth of human prostate carcinoma cell line PC-3
Artículo
Open/ Download
Publication date
2009Metadata
Show full item record
Cómo citar
Parra, Eduardo
Cómo citar
Down-regulation of Egr-1 by siRNA inhibits growth of human prostate carcinoma cell line PC-3
Abstract
The inhibitory effect of a specific small EGR-1
interfering RNA (siRNA) on cell proliferation and the
expression of EGR-1 in human prostate carcinoma cell lines
PC-3 and LNCaP was investigated. To knockdown Egr-1
expression, a siRNA targeting against Egr-1 was synthesized
and transfected into PC-3 and LNCaP cells. The downregulation
of Egr-1 expression at both mRNA and protein
levels were detected by reverse transcription-polymerase
chain reaction (RT-PCR) and Western blot analysis. The
transcription activity was determined by luciferase expression.
Cell proliferation inhibition rates were determined by
soft agar and methyl thiazolyl tetrazolium (MTT) assay. The
effect of Egr-1 siRNA on cell cycle distribution and cell
apoptosis was determined by flow cytometry (FCM). RNA
interference efficiently suppressed the Egr-1 expression in
PC-3 and LNCaP cells. At 96 h after transfection, the
expression inhibition rate was 44.52% at mRNA level detected
by RT-PCR and 40.17% at protein level by Western blot
analysis. The cell proliferation inhibition rates at 24, 48, 96
and 120 h after Egr-1 siRNA and non-silencing siRNA
transfection, were 5, 25.06, 65.61 and 78.36%, respectively
for PC-3 cells and 23, 40.3, 75.9 and 67.4%, respectively for
LNCaP cells. The apoptosis rate was similar for both PC-3
and LNCaP and the number of cells was increased in G0/G1
phase from 38.2 to 88.6%, and decreased in S and G2/M
phase at 96 h after transfection. Down-regulation of Egr-1
results in significant inhibition of tumor growth in vitro. The
inhibition of Egr-1 expression can induce apoptosis of PC-3
cells. The use of Egr-1 siRNA deserves further investigation
as a novel approach to cancer therapy.
General note
Artículo de publicación ISI
Quote Item
ONCOLOGY REPORTS 22: 1513-1518, 2009
Collections